Dupilumab Prefilled Syringe [Dupixent]
RxNorm 1876404

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1876404 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: dupilumab Prefilled Syringe [Dupixent].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDF
Dupilumab Prefilled Syringe [Dupixent]
AUI:8741875

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDFPrescribable

Semantic Branded Drug Form (SBDF):
Dupilumab Prefilled Syringe [Dupixent]
(Atom ID: 8741875)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
dupilumab Prefilled Syringe [Dupixent]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1876404
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
8741875
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDF
Semantic Branded Drug Form (Ingredient + Dose Form + Brand Name)
Source Code
1876404
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Dupilumab Injection


Dupilumab injection is used to treat the symptoms of eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children 6 years and older who cannot use other medications for their condition or whose eczema has not responded to other medications. It is also used along with other medications to prevent wheezing, shortness of breath, coughing, and chest tightness due to certain types of asthma in adults and children 12 years and older whose symptoms are not controlled with other medications. Dupilumab injection is also used along with other medications to treat chronic rhinosinusitis with nasal polyposis (ongoing runny nose, sinus swelling and/or nasal congestion, with or without a reduced sense of smell or pain and pressure in the face) in adults whose symptoms are not controlled with other medications. Dupilumab injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain substances in the body that cause the symptoms of eczema.
[Learn More]


* Please review the disclaimer below.